# Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct05562297/  
OnCo record `nct05562297` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05562297 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 50 participants, started 2025-03-20 and due to reach its primary completion in 2027-10-01. Interventions recorded: sintilimab; nab-paclitaxel; gemcitabine. Conditions listed: Pancreatic Cancer, Stage IB; Pancreatic Cancer, Stage IIA; Pancreatic Cancer, Stage IIB; Pancreatic Cancer Stage III. Primary outcome: 2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel. Pancreatic eligibility wording from the registry: "* Patients must have imaging evaluations to confirm that their pancreatic adenocarcinoma is resectable and borderline resectable". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05562297
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined With Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients With Resectable and Borderline Resectable Pancreatic Cancer
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05562297: https://clinicaltrials.gov/study/NCT05562297

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05562297.json